Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
Stocks in this Quantisnow insightHealth Care
Historical context for OCS
Across the 22 sessions after earlier OCS headlines, the stock closed higher 15 times and lower 6 times, with a median move of 3.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | OCS | SPY |
|---|---|---|---|
| Jun 2, 2026 | OCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law Violations | -15.3% | +0.1% |
| May 29, 2026 | Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema | -23.4% | +0.2% |
| May 21, 2026 | Guggenheim initiated coverage on Oculis Holding AG with a new price target | +11.1% | +0.2% |
| May 15, 2026 | Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors | +0.2% | -1.2% |
| May 12, 2026 | Oculis Reports Q1 2026 Financial Results and Provides Company Update | -6.9% | -0.2% |
| May 7, 2026 | Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial | +5.1% | -0.3% |
Quantisnow market dataNASDAQ
OCS
Oculis Holding AG
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for OCS
Full OCS profile on Quantisnow Follow OCS and get a push notification the moment its next story breaks.